Overview

Public BiotechPhase 4LSDketaminepsilocybinHiring

Formerly MindMed, rebranded to Definium Therapeutics in January 2026. Developing DT120 (LSD) for generalized anxiety disorder and major depressive disorder. Three Phase 3 readouts expected in 2026.

Visit Website

New York, NY

$450M
Market Cap
2019
Founded
80
Employees
10
Open Roles

Open Positions(10)

Associate Director, Clinical Scientist
Remote
Executive Director, Late Stage Clinical Strategy
Remote
Medical Director, Early Phase and PK
Remote
Director, Medical Safety PV
Remote
Senior, Clinical Trial Manager
Remote
Associate Director, Medical Writing
Remote
Vice President, Programs and Portfolio Office(PPO)
Remote
Senior R&D System Administrator
Remote
Associate Director, Statistical Programming
Remote
Senior Director, Medical Affairs Publications
Remote

Clinical Pipeline(4)

Recruiting·Phase 3·LSD

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

PlaceboGeneralized Anxiety Disorder
NCT06741228
Not Yet Recruiting·Phase 4·ketamine

An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium

Esketamine combined with dexmedetomidineDexmedetomidine
NCT07377981
Unknown·Phase 4·ketamine

Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma

EsketamineHepatocellular Carcinoma
NCT05416073
Unknown·Early Phase 1·psilocybin

A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients

Psilocybin-assisted therapy within a community of practice model (group administered)End of Life
NCT05958758